SCHEMBL7187022

SCHEMBL7187022

COc1cc(OC)c(C(=O)Pc2c(OC(C)(C)C)cc(OC(C)(C)C)cc2OC(C)(C)C)c(OC)c1.[LiH]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 2/20 0.38
ABCG2 Q9UNQ0 5/20 0.38
CYP2D6 P10635 2/20 0.34
CYP2C19 P33261 1/20 0.34
LMNA P02545 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
ADRA2C P18825 1/20 0.33
OPRK1 P41145 1/20 0.33
KCNH2 Q12809 1/20 0.33
EBP Q15125 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
NFKB1 P19838 1/20 0.33
DPP4 P27487 1/20 0.33
NFKB2 Q00653 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185559 0.89 CA12 (0.41) CYP3A4MAPK1SMN1; SMN2KMT2AABCG2
SCHEMBL7174584 0.85 CYP3A4 (0.50) CYP3A4USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL7188721 0.83 CA12 (0.38) ABCG2KCNH2MAPT
SCHEMBL7183190 0.83 KMT2A (0.44) CYP3A4USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL7180710 0.82 KMT2A (0.43) CYP3A4USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL7175924 0.81 POLB (0.37) ABCG2LMNAMAPT
SCHEMBL7182290 0.81 KDM4E (0.32) CYP2C19
Lithium SCHEMBL7183198 0.80 KMT2A (0.44) CYP3A4USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL7181159 0.80 TRPM4 (0.30)
SCHEMBL7188938 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 CYP3A4 1652/4885USP2 4168/4885MAPK1 1801/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 CYP3A4 1881/4885USP2 3362/4885MAPK1 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.